CD19 CAR T-cell therapy for lymphoma

preview_player
Показать описание
Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany discusses CD19 CAR T-cell therapy against acute- and non-Hodgkin lymphoma. Being the 4th trial of its kind worldwide, Prof. Schmitt examines the need for new technology therapies to prevent patient relapse. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Michael Schmitt
  3. Event: EBMT 2019
  4. Format: Interview
  5. Subject: Lymphoma
  6. Subject: Non-Hodgkin Lymphoma
Рекомендации по теме
CD19 CAR T-cell 0:02:55

CD19 CAR T-cell therapy for lymphoma

CD19- and CD22-Directed 0:02:36

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

Bispecific CAR T-cell 0:00:45

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

Dr. Shah on 0:01:29

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell Therapies

CD19 CAR T 0:57:03

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

Anti-CD22 CAR T-cell 0:01:21

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status

Dr. Smith Discusses 0:00:56

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

CD19 Targeted CAR 0:45:46

CD19 Targeted CAR T-cell Therapy in LBCL

Advancements and challenges 0:02:53

Advancements and challenges in CAR-T cell therapy

Safety profile of 0:01:11

Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel

Lymphoma: Overview of 0:06:13

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells

CD19 CAR T 0:18:59

CD19 CAR T Cell Therapy in SLE (9.16.2022)

Key questions in 0:04:24

Key questions in the field of CD19 CAR T-cell therapy

CD19 CAR T-cells 0:04:47

CD19 CAR T-cells for adults

Prior blinatumomab use 0:03:42

Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL

CAR T-Cell Therapy: 0:02:21

CAR T-Cell Therapy: How Does It Work?

Humanized versus murinized 0:03:34

Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma

Risk factors to 0:04:05

Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL

CD19 CAR-T for 0:01:39

CD19 CAR-T for CNS lymphoma

CD19 CAR-T for 0:06:01

CD19 CAR-T for lymphoma: real-world experience in the UK

CD19-Targeted CAR T-Cell 0:08:33

CD19-Targeted CAR T-Cell Therapy in Managing DLBCL

CAR T Cell 0:05:17

CAR T Cell Therapy for Autoimmune Disease

Diminished chronic GvHD 0:01:57

Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study

Efficacy of bispecific 0:02:37

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies